ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,275Medicare Part D Prescriptions Filled, Including Refills

Rank: 51 out of 223

$601K Total Retail Price of All Prescriptions

Rank: 42 out of 223

439 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Utah
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 439 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

13% of this provider’s 439 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

3% of this provider’s 7,924 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$65 was the average price of a prescription from this provider, compared to $62 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Utah
SIMVASTATIN 449 386 1 1
LEVOTHYROXINE SODIUM 441 423 2 2
OMEPRAZOLE 340 307 3 3
HYDROCODONE-ACETAMINOPHEN 332 238 S3 4 5
METFORMIN HCL 309 240 5 7
LISINOPRIL 261 200 6 4
AMLODIPINE BESYLATE 213 206 7 6
POTASSIUM CHLORIDE 179 162 8 12
WARFARIN SODIUM 173 144 9 11
ALENDRONATE SODIUM 167 167 10 19
ZOLPIDEM TARTRATE 161 161 11 8
HYDROCHLOROTHIAZIDE 143 137 12 13
FUROSEMIDE 112 92 13 9
LEVOXYL 104 103 14 78
MELOXICAM 104 93 14 33
CELEBREX 103 82 16 42
LOSARTAN-HYDROCHLOROTHIAZIDE 103 102 16 31
METOPROLOL SUCCINATE 101 101 18 20
SYNTHROID 97 97 19 35
LISINOPRIL-HYDROCHLOROTHIAZIDE 96 90 20 29
CITALOPRAM HBR 96 52 20 16
TAMSULOSIN HCL 94 93 22 26
GABAPENTIN 91 83 23 10
LOSARTAN POTASSIUM 85 76 24 14
ATORVASTATIN CALCIUM 83 83 25 17
NAMENDA 81 81 26 48
SERTRALINE HCL 76 73 27 21
LYRICA 69 55 28 84
PRAVASTATIN SODIUM 67 65 29 15
POLYETHYLENE GLYCOL 3350 66 57 30 69
ATENOLOL 66 53 30 32
JANUVIA 63 50 32 66
TRAMADOL HCL 61 61 33 18
FENOFIBRATE 61 56 33 38
CARISOPRODOL 59 0 R 35 63
ACTONEL 57 57 36 166
DIPHENOXYLATE-ATROPINE 55 18 37 240
BENAZEPRIL HCL 55 55 37 57
VERAPAMIL ER 55 48 37 89
PANTOPRAZOLE SODIUM 54 47 40 45
DIOVAN 52 52 41 54
ESTRADIOL 52 30 R 41 59
METOPROLOL TARTRATE 52 49 41 25
TEKTURNA 50 50 44 255
AMLODIPINE BESYLATE-BENAZEPRIL 50 50 44 105
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 1, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.